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Abstract
Introduction: Cystic fibrosis afflicted lungs support the growth of many bacteria rarely implicated
in other cases of human infections.
Case presentation: We report the isolation and identification, by 16S rRNA amplification and
sequencing, of two emerging pathogens resistant to colistin, Brevundimonas diminuta and
Ochrobactrum anthropi, in a 17-year-old woman with cystic fibrosis and pneumonia. The patient
eventually responded well to a 2-week regime of imipenem and tobramycin.
Conclusion: Our results clearly re-emphasize the emergence of new colistin-resistant pathogens
in patients with cystic fibrosis.
Introduction
Cystic fibrosis (CF) is one of the most common auto-
somal-recessive hereditary diseases in Europeans and is
characterized by disorders of the respiratory tract and pan-
creas, and exacerbations of pulmonary infections. A lim-
ited number of organisms are responsible for these
infections, with Staphylococcus aureus and Pseudomonas aer-
uginosa  being of primary importance. Recent studies,
using molecular approaches, have identified uncommon
bacteria and/or novel pathogens in patients with CF [1]
including strains resistant to colistin such as Stenotropho-
monas maltophilia, Achromobacter xylosoxidans, Burkholderia
cepacia and Inquilinus limosus [2]. While the frequency of
infection with these species is believed to be relatively low
and their significance unclear, they present a real chal-
lenge to diagnostic laboratories, as they are difficult to
identify and often misidentified as belonging to the Bur-
kholderia cepacia complex [1,3]. We report the isolation
and identification, by 16S rRNA sequencing, of two
emerging pathogens resistant to colistin, Brevundimonas
diminuta  and  Ochrobactrum anthropi in a 17-year-old
patient with cystic fibrosis and pneumonia. The study was
approved by the local ethics committee (IFR48).
Case presentation
A 17-year-old woman with cystic fibrosis, and with diabe-
tes and persistent colonization of the respiratory tract with
Staphylococcus aureus since childhood was admitted in
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October 2006 to our specialized centre for a respiratory
infection with dark sputum, asthenia, fever (38.5°C) and
a loss of weight of 4.5 kg. On examination, the patient had
shortness of breath and diffuse crepitations in both lungs.
The oxygen saturation on air was 92% and her chest X-ray
showed a diffuse bronchitis syndrome with bronchial dis-
tension in the right lung apex and left lung base. There was
no pleural effusion. Relevant laboratory findings included
a white blood cell (WBC) count of 18,380/mm3 with
82.8% polymorphonuclear cells (PMNs), a platelet count
of 618,000/mm3, C-reactive protein (CRP) of 57 mg/litre,
fibrinogen of 5.17 g/litre and whole blood glucose of 9
mmol/litre. An admission sputum sample was plated
onto Columbia colistin-nalidixic acid (CNA) agar, choco-
late Poly ViteX agar, MacConKey agar (bioMérieux, Marcy
l'Etoile, France), CEPACIA agar, and SABOURAUD agar
(AES laboratory, Combourg, France). Direct Gram stain-
ing of the sputa showed numerous PMNs (>25 cells/
field), Gram-positive cocci, and infrequent epithelial cells
(<10 cells/field). Apart from 107 CFU/ml methicillin-sus-
ceptible S. aureus, two different Gram-negative rods (oxi-
dase and catalase positive) were isolated from CEPACIA
agar at 103 CFU/ml after 3 days of incubation. Using API
20NE (bioMérieux, Marcy l'Etoile, France), two isolates
initially identified as Weeksella virosa /Empedobacter brevis
(Code 0010014, 84.5% probability) and Ochrobactrum
anthropi (code 1641344, 98.9% probability) were defini-
tively identified as B. diminuta (100% homology with B.
diminuta strain DSM 1635, GenBank accession number
X87274) and O. anthropi (100% homology with O.
anthropi  strain W24, GenBank accession number
EF198140), respectively, after amplification and sequenc-
ing of the 16S rRNA gene as previously described [4].
Although there is neither clear consensus nor guidelines
for antibiotic susceptibility testing (AST) of these two bac-
teria, AST was performed using VITEK 2 Auto system
(bioMérieux, Marcy l'Etoile, France) and disc diffusion
methods. The B. diminuta was resistant to amoxicillin,
amoxicillin/clavulanic acid, ceftazidime, ciprofloxacin,
trimethoprim/sulphamethoxazole and colistin but
remained susceptible to ceftriaxone, ticarcillin, ticarcillin/
clavulanic acid, imipenem, amikacin, tobramycin, gen-
tamicin, isepamicin, rifampicin, and piperacillin/tazo-
bactam. The O. anthropi was resistant to amoxicillin,
amoxicillin/clavulanic acid, ticarcillin, ticarcillin/clavu-
lanic acid, ceftazidime, ceftriaxone, piperacillin/tazo-
bactam and colistin but remained susceptible to
ciprofloxacin, imipenem, amikacin, tobramycin, gen-
tamicin, isepamicin, trimethoprim/sulphamethoxazole
and rifampicin. The patient was initially treated with
ceftazidime (2 g 4 times/day) and nebulized tobramycin
(300 mg/day) for 2 weeks. The treatment was switched to
intravenous imipenem (4 g/day) and tobramycin (320
mg/day) for 2 weeks with dramatic improvement. Two
weeks later, the patient was clinically well and sputum
culture yielded a mixed oral population. B. diminuta and
O. anthropi were not cultured again in 5 sputa investigated
during 7 months of follow-up.
Discussion
B. diminuta is a non-lactose-fermenting environmental
Gram-negative bacillus previously assigned to the genus
Pseudomonas (Figure 1) that has been occasionally impli-
cated in clinical situations in immunocompetent and
immunocompromised hosts including bacteraemia, uri-
nary infection and emphysema [5,6]. In a study by Kiska
et al. [3], B. diminuta was isolated in a patient with cystic
fibrosis, after being misidentified as B. cepacia, but the
identification was not performed using molecular meth-
ods and the patient's clinical condition was not reported
[3]. O. anthropi is a Gram-negative non-fermenting bacil-
lus widely distributed in the environment that has rarely
been reported as a human pathogen. It has been impli-
cated in several clinical situations in immunocompetent
and immunocompromised hosts including osteochondri-
tis, necrotizing fasciitis, endophthalmitis, cellulitis, sepsis,
chest wall abscess, osteomyelitis, endocarditis and pelvic
abscess [7-9]. O. anthropi is characterized by a broad spec-
trum of antibiotic resistance and is believed to be natu-
rally susceptible to colistin [10] whereas there are
currently no available data for AST of B. diminuta. It
should be noted that our patient received a course of col-
istin to treat a A. xylosoxidans colonization 10 months
before the onset of this pneumonia. This may have con-
tributed to the selection of these two colistin-resistant bac-
teria in our patient. We believe that these two colistin-
resistant pathogens were the main cause of her acute
pneumonia. Although S. aureus may also partially partici-
pate in the pathogenic process, O. anthropi and B. diminuta
were isolated during this pneumonia. Moreover, the
patient did not improve initially with an effective antibio-
therapy against S. aureus (ceftazidime) and improved
using an effective antibiotic treatment against the two col-
istin/ceftazidime-resistant strains suggesting a role of one
or both colistin-resistant strains as an agent of lower res-
piratory tract infection in this patient.
Conclusion
Our results clearly re-emphasize the emergence of new
colistin-resistant pathogens in patients with cystic fibrosis
as recently reported for Inquilinus limosus [2]. The
increased clinical use of nebulized colistin in patients
with cystic fibrosis may select specific colistin-resistant
bacteria. Furthermore, the use of Burkholderia cepacia com-
plex selective agar associated with molecular approaches
may allow the identification of emerging colistin-resistant
pathogens in patients with cystic fibrosis.
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Phylogenetic tree based on 16S rRNA sequences Figure 1
Phylogenetic tree based on 16S rRNA sequences. The information presented includes bacterial species or phylotype and Gen-
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